Search

Background: The risk for worse outcomes of COVID-19 (Coronavirus 2019 disease) is higher in patients with cardiac conditions. In this study, we aim to investigate the risks of COVID-19-induced conditions in cases with underlying heart failure.

Background: Neurogenic dysfunction of the lower urinary tract is one of the challenging diseases with high burdens in urology. Our study aims to evaluate the efficacy of a 4-week treatment with Solifenacin and Trospium chloride and assess their safety and impact on quality of life., Methods: Following the selection of 206 stroke patients from two centers who met specific eligibility criteria, including a clinical diagnosis of stroke, normal cognitive function, and the presence of lower urinary tract symptoms (LUTS), participants were randomly assigned to receive oral Solifenacin, Trospium chloride, or a placebo. Under the supervision of the Ethics Committee, the baseline characteristics, compliance with medication, and outcomes were monitored, gathered, and analyzed., Results: The majority of participants were male, with a mean age of 67.3, and most had ischemic stroke. The groups had no significant difference in urinary symptoms after stroke. All of the symptoms in the study groups, according to the NBSS questionnaire, were decreased following treatment compared to the baseline (p < 0.05). After treatment, ICIQ-OAB, and ICIQ-LUTS-QOL total scores and bothersome scores decreased significantly compared to baseline (p < 0.001). When compared to the placebo, both Trospium chloride and Solifenacin alleviated symptoms according to the NBSS questionnaire and ICIQ-LUTS-QOL, total ICIQ-OAB, and the total score of ICIQ-OAB-Bothersome. However, the total LUTS-QOL-Bothersome score did not change in the active treatment groups compared to the placebo. While comparing the two drugs, these values were similar except for the total score of LUTS-QOL-Bothersome, ICIQ-OAB, and ICIQ-OAB-Bothersome in favor of the Solifenacin group. Moreover, Solifenacin had fewer side effects compared to Trospium chloride or placebo., Conclusion: The study analyzed 206 stroke patients in two international centers and found both drug arms effective in treating overactive bladder. However, inconsistencies were found in efficacy and safety, necessitating further studies with larger populations., Trial Registration: This triple-blind, multicenter, randomized controlled trial was done on 206 stroke patients after getting Ethical Committee approval and registering the project on IRCT (IRCT20160606028304N2)., (© 2024 Wiley Periodicals LLC.)

Meningitis and meningoencephalitis, as inflammatory diseases of the brain parenchyma, are serious events reported sporadically after coronavirus disease 2019 (COVID-19) vaccination. However, there is a lack of systematic reviews consolidating these reported cases. By using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive search was conducted across PubMed, Scopus, Embase, and Web of Science databases. All case reports and series discussing the emergence of meningitis and meningoencephalitis after COVID-19 vaccination were included and evaluated using the Joanna Briggs Institute critical appraisal tool. Out of 967 records, 27 studies with 31 patients were eventually included. The most commonly reported symptoms were headaches and fever. About one-third of the patients exhibited positive meningeal signs. Most of the findings in the computed tomography scans and magnetic resonance images revealed no significant changes or enhancement in the leptomeninges. Cerebrospinal fluid analysis dominantly suggested aseptic meningitis, and about 80.6% of the patients experienced a full recovery. After a detailed review of the reported cases, further research is needed to establish a definitive correlation between meningitis and COVID-19 vaccination on a larger scale.